Gene · 3912
LAMB1: laminin subunit beta 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. LAMB1: laminin subunit beta 1. Genes, record 3912. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3912
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P07942 | Laminin subunit beta-1 | 1,786 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents71
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 51111 | P07942 | Espacenet |
| WO 2025259943 A1 | 2025-12-18 | 13 | P07942 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 557 | P07942 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 394 | P07942 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 7677 | P07942 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6854 | P07942 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6854 | P07942 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 394 | P07942 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 557 | P07942 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 30693 | P07942 | Espacenet |
1 to 10 of 71
See all 71 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| OCRIPLASMIN | CHEMBL2095222 | Laminin hydrolytic enzyme | HYDROLYTIC ENZYME |
Source ChEMBL
Trials10
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT02747030 | OCRIPLASMIN | PHASE1 | ClinicalTrials.gov | |
| NCT02681809 | OCRIPLASMIN | PHASE2 | 2020-12-16 | ClinicalTrials.gov |
| NCT01429441 | OCRIPLASMIN | PHASE3 | 2016-01-11 | ClinicalTrials.gov |
| NCT00996684 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov | |
| NCT00798317 | OCRIPLASMIN | PHASE3 | 2013-01-30 | ClinicalTrials.gov |
| NCT00781859 | OCRIPLASMIN | PHASE3 | 2013-01-28 | ClinicalTrials.gov |
| NCT00428129 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov | |
| NCT00412451 | OCRIPLASMIN | PHASE2 | 2013-09-13 | ClinicalTrials.gov |
| NCT00123305 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov | |
| NCT00123266 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov |
NIH grants1,309
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | LAMB1 papers | Newest fiscal year |
|---|---|---|---|
| P30DK043351 | Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital | 6 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 5 | 2025 |
| U01DK062413 | Determining genomic and host-environment contributions to IBD phenotypes | 5 | 2025 |
| U01DK062422 | Mount Sinai NYC Genetics Research Center: Multi-omic integration across data-types, cell niches and populations | 5 | 2025 |
| U01DK062431 | IBD Gene Mapping by Clinical and Population Subset | 5 | 2025 |
| P20GM103418 | Kansas IDeA Network of Biomedical Research Excellence 5 | 4 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 4 | 2025 |
| U01DK062423 | Genomic and Immunologic Characterization of Inflammatory Bowel Disease and its Phenotypes | 4 | 2025 |
| U01DK062432 | Montreal-Boston Collaborative GRC | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,309Source NIH's project files
See all 1,309 nih grantsPapers1,743
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exosome-Mediated Bidirectional Signaling Regulates Glioma Stem-Cell Homeostasis and Radiation-Induced Plasticity. | bioRxiv | 2026 | 42818566 | PubTator, text mining | PubMed |
| Combination of Blastocyst Complementation and Omics Allows Fast Evaluation of Human Pathogenic Mutations in Mice. | Am J Respir Cell Mol Biol | 2026 | 42814875 | PubTator, text mining | PubMed |
| SRPK Inhibition in Cholangiocarcinoma Cells Induces LAMB1-Associated Adaptive Responses and Enhances Growth Suppression by the MEK Inhibitor U0126 via the LAMB1/ERK/c-JUN Axis. | Front Biosci (Landmark Ed) | 2026 | 42811991 | PubTator, text mining | PubMed |
| Tumor Vascular Features and Colorectal Cancer-Specific Mortality. | JAMA Netw Open | 2026 | 42804694 | PubTator, text mining | PubMed |
| [Mechanistic role of spinal Lamb1 in negative emotion-facilitated neuropathic pain regulated by the ACC-SDH pathway]. | Zhong Nan Da Xue Xue Bao Yi Xue Ban | 2026 | 42763294 | PubTator, text mining | PubMed |
| Investigating the Cellular Activity and Differential Gene Expression of Human Astrocytes in Interaction with Protein Composite Nanofibers. | Neurochem Res | 2026 | 42599588 | PubTator, text mining | PubMed |
| Biallelic Frameshift Variant in LAMB1 Associated with Occipital Meningoencephalocele and Pansutural Craniosynostosis: A Case Report and Review of the Literature. | Pediatr Dev Pathol | 2026 | 42593106 | PubTator, text mining | PubMed |
| Integrative multi-omics analysis identifies stellate cell-derived complement component 7 as a predictor of fibrosis and liver-related events in MASLD. | JHEP Rep | 2026 | 42486350 | PubTator, text mining | PubMed |
| [Combined analysis of epigenetic and transcriptomic data from children with Wiedemann-Steiner syndrome due to variants of KMT2A gene]. | Zhonghua Yi Xue Yi Chuan Xue Za Zhi | 2026 | 42342635 | PubTator, text mining | PubMed |
| Construction of a diagnostic model for nasopharyngeal carcinoma using a consensus machine learning approach and study of immune infiltration characteristics. | Discov Oncol | 2026 | 42303913 | PubTator, text mining | PubMed |
1 to 10 of 1,743
See all 1,743 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3912
GET https://conductscience.org/api/genes/v1/3912/patents?page=2